FIGURE 7 from Nuclear Export Inhibitor Selinexor Enhances Oncolytic Myxoma Virus Therapy against Cancer

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Selinexor enhances MYXV replication in vivo in xenograft tumors in NSG mice and reduces tumor burden. A, Diagram of experimental setup. NSG mice were inoculated with Colo205 or HT29 cells at day 0 via subcutaneous injection on both flanks. Animals received three doses of selinexor by oral gavage and three intratumoral injection of vMyx-FLuc on the left flank. Mice were imaged for luciferase activity 48 hours after first and second virus injection. B, Luminescence images taken using IVIS imaging system 48 hours after the first injection. C, Quantification of luminescence signals as relative light units (RLU) from images taken 48 hours after first injection. D, Luminescence images taken using IVIS imaging system 48 hours after the second injection. E, Quantification of luminescence signals as RLU from images taken 48 hours after second injection. F–G, Tumor volumes on the left and the right flanks were measured at different days after the start of treatments. Results are presented as mean ± SEM. ns, P > 0.05; *, P < 0.05; **, P < 0.01.